Breast cancer is the most common form of cancer worldwide. Many patients first undergo neoadjuvant therapy (such as chemotherapy or hormone therapy) to shrink the tumor before surgery. However, not everyone responds well to this treatment, causing some patients to experience unnecessary side effects without effective results.
Researchers at the Netherlands Cancer Institute (NKI) have developed an innovative AI model, called Multi Modal Response Prediction (MRP), to address this issue. Published in Nature Communications, the study highlights how this AI model improves treatment decisions by combining multiple data sources, such as radiological images, tumor characteristics, and clinical data.
Unlike traditional AI models that rely on a single data type, MRP integrates multiple forms of patient information to predict whether neoadjuvant therapy will be effective. This allows doctors to:
One key advantage of MRP is its ability to not only predict outcomes but also explain why it reaches its conclusions. This transparency increases trust among physicians and enables better-informed decisions.
By leveraging AI, MRP reduces physicians’ workload, accelerates treatment decisions, and improves patient outcomes. Researchers are now working to implement this model in clinical practice, making personalized breast cancer treatment a reality.
Read also
